Skip to main content
Erschienen in: PharmacoEconomics 9/2006

01.09.2006 | Editorial

US FDA Guidance

Apropos of PROs

verfasst von: Professor Paul Kind

Erschienen in: PharmacoEconomics | Ausgabe 9/2006

Einloggen, um Zugang zu erhalten

Excerpt

For centuries past, the appearance of a new stellar object has been regarded as the harbinger of doom, Halley’s Comet being but one example of a worldwide phenomenon with a socio-political impact that is recorded across history. The arrival of US FDA guidance on ‘patient-reported outcomes’ has been anticipated for some time past, not least by those in outcomes research, academia and industry who participated in the preliminary close encounters that provided the motive power which fuelled its evolution. This background is important in locating the present guidance document since it provides an insight into unresolved issues. …
Literatur
1.
Zurück zum Zitat Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient’s perspective into drug development and communication: PRO Harmonization Group. Value Health 2003; 6 (5): 522–531PubMedCrossRef Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient’s perspective into drug development and communication: PRO Harmonization Group. Value Health 2003; 6 (5): 522–531PubMedCrossRef
2.
Zurück zum Zitat Giuliani RW. The next phase of quality of life: creating a more civil city. New York, 1998 Feb 22 [online]. Available from URL: http://www.nyc.gov/html/rwg/html/98a/quality.html [Accessed 2006 Aug 17] Giuliani RW. The next phase of quality of life: creating a more civil city. New York, 1998 Feb 22 [online]. Available from URL: http://​www.​nyc.​gov/​html/​rwg/​html/​98a/​quality.​html [Accessed 2006 Aug 17]
3.
Zurück zum Zitat US Department of Health and Human Services Food and Drug Administration. Draft guidance for industry on patient-report-ed outcome measures: use in medical product development to support labeling claims [online]. Available from URL: http:// www.fda.gov/CDER/guidance/5460dft.pdf [Accessed 2006 Aug 17] US Department of Health and Human Services Food and Drug Administration. Draft guidance for industry on patient-report-ed outcome measures: use in medical product development to support labeling claims [online]. Available from URL: http:// www.fda.gov/CDER/guidance/5460dft.pdf [Accessed 2006 Aug 17]
Metadaten
Titel
US FDA Guidance
Apropos of PROs
verfasst von
Professor Paul Kind
Publikationsdatum
01.09.2006
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 9/2006
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200624090-00001

Weitere Artikel der Ausgabe 9/2006

PharmacoEconomics 9/2006 Zur Ausgabe